Less Ads, More Data, More Tools Register for FREE

Pin to quick picksAstrazeneca Share News (AZN)

Share Price Information for Astrazeneca (AZN)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 6,900.00
Bid: 6,899.00
Ask: 6,900.00
Change: 42.00 (0.61%)
Spread: 1.00 (0.01%)
Open: 6,927.00
High: 6,927.00
Low: 6,853.00
Yest. Close: 6,858.00
AZN Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

RNS Alerts are a premium feature

Login to your account

myTerminal is a premium feature

Login to your account

Don't have an account? Click here to register.

AstraZeneca to buy 55 pct of cancer firm Acerta for $4.0 bln

LONDON, Dec 17 (Reuters) - AstraZeneca said on Thursday it had agreed to buy a 55 percent stake in privately held biotech firm Acerta Pharma for $4.0 billion to give it access to a new kind of drug for fighting blood cancers. AstraZeneca will pay $2.5 billion upfront, with a further $1.5 bi

17 Dec 15 07:40

AstraZeneca To Pay USD4 Million For Majority Of Acerta Pharma

17 Dec 15 07:13

AstraZeneca buys majority stake in Acerta Pharma to expand oncology portfolio

(ShareCast News) - AstraZeneca has announced it will acquire a 55% stake in Acerta Pharma over its oncology treatment - a deal valued at $4bn (£2.7bn). The deal will give the FTSE 100 pharmaceutical company access to the privately-owned US and Netherlands based biopharmaceutical company's acalabruti

17 Dec 15 07:08

Polar Capital Global Healthcare Trust Managers Affirm Belief In Target

16 Dec 15 10:38

UPDATE 1-AstraZeneca boosts respiratory unit with $575 mln Takeda deal

(Adds further details) LONDON, Dec 16 (Reuters) - Britain's AstraZeneca has agreed to buy Takeda Pharmaceutical's respiratory business, including expanded rights to roflumilast, a treatment for chronic obstructive pulmonary disease (COPD). AstraZeneca, which has marketed roflumilast i

16 Dec 15 08:28

AstraZeneca to acquire Takeda Pharmaceutical Company for drug rights

(ShareCast News) - AstraZeneca will acquire the core respiratory business of Takeda Pharmaceutical Company for $575m (£382m). The deal includes the expansion of rights to chronic obstructive pulmonary disease (COPD) treatment roflumilast, also known as Daliresp in the US and Daxas elsewhere. The FT

16 Dec 15 07:48

AstraZeneca boosts respiratory unit with $575 mln Takeda deal

LONDON, Dec 16 (Reuters) - Britain's AstraZeneca has agreed to buy Takeda Pharmaceutical's respiratory business, including expanded rights to roflumilast, a treatment for chronic obstructive pulmonary disease (COPD). AstraZeneca, which has marketed roflumilast in the United States under the

16 Dec 15 07:38

AstraZeneca Snaps Up Takeda's Respiratory Unit For USD575 Million

16 Dec 15 07:25

AstraZeneca investing $800 mln to go local in China

By Ben Hirschler LONDON, Dec 16 (Reuters) - AstraZeneca aims to build up its already strong position in China by making and developing more medicines locally, and will invest more than $800 million in the country over the next 10 years, it said on Wednesday. The British drugmaker's de

16 Dec 15 06:00

Astrazeneca completes disposal of Entocort

(ShareCast News) - AstraZeneca has received a $380m payment from Irish competitor Perrigo as the FTSE 100 company completed the disposal of right for a Crohn's disease medicine. Perrigo last month agreed to buy the US rights from AstraZeneca to sell Entocort capsules and generic Entocort capsules ma

15 Dec 15 15:20

AstraZeneca Sells US Rights For Crohn's Medicine Entocort To Perrigo

15 Dec 15 15:12

UPDATE 2-AstraZeneca chases Acerta to secure next cancer drug winner

* AstraZeneca confirms talks with biotech firm Acerta * Signals determination to build up cancer drug business * "No certainty" that any deal will be agreed (Adds comment on other potential bidders for Acerta) By Ben Hirschler LONDON, Dec 14 (Reuters) - AstraZeneca said

14 Dec 15 13:59

UPDATE 1-AstraZeneca chases Acerta to secure next cancer drug winner

* AstraZeneca confirms talks with biotech firm Acerta * Signals determination to build up cancer drug business * "No certainty" that any deal will be agreed (Adds analyst comment, detail on Acerta drug) By Ben Hirschler LONDON, Dec 14 (Reuters) - AstraZeneca said on Mond

14 Dec 15 09:16

AstraZeneca confirms talks with biotech group Acerta

(ShareCast News) - Pharmaceuticals giant AstraZeneca confirmed that it is exploring potential strategic options with biotech company Acerta Pharma BV. "There can be no certainty that any transaction will ultimately be entered into, or as to the terms of any transaction," AZN said. The statement fol

14 Dec 15 08:14

AstraZeneca confirms talks with cancer drug firm Acerta

LONDON, Dec 14 (Reuters) - AstraZeneca said on Monday it was in talks with privately held cancer drug developer Acerta Pharma, after the Wall Street Journal reported on Friday it was looking to acquire the business for more than $5 billion. "AstraZeneca confirms that it is exploring potenti

14 Dec 15 08:08

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.